Boston Scientific Corp (BSX)

Currency in USD
48.18
+1.45(+3.10%)
Real-time Data·
BSX is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
47.5048.92
52 wk Range
42.20109.50
Key Statistics
Prev. Close
46.73
Open
47.83
Day's Range
47.5-48.92
52 wk Range
42.2-109.5
Volume
10.65M
Average Volume (3m)
20.9M
1-Year Change
-54.2643%
Book Value / Share
17.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BSX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
62.69
Upside
+30.12%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Boston Scientific Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

26 Buy
5 Hold
0 Sell
Ratings:
31 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 62.69
(+30.12% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Argus
Hold---Downgrade31/07/2026
UBS
Buy67.00+39.18%74.00Maintain30/07/2026
JPMorgan
Buy56.00+16.33%80.00Maintain30/07/2026
TD Cowen
Buy56.00+16.33%61.00Maintain30/07/2026
RBC Capital
Buy70.00+45.41%85.00Maintain30/07/2026

Boston Scientific Corp SWOT Analysis


Market Dominance
Boston Scientific's impressive 21.44% revenue growth and 20% organic growth highlight its strong market position and effective growth strategies
Strategic Acquisitions
Explore BSX's expansion into high-growth areas like renal denervation and neuromodulation through strategic acquisitions of SoniVie and Axonics
Analyst Optimism
With a consensus recommendation of 1.36, analysts project significant margin expansion and a weighted average market growth rate of 8.5% for 2025
Navigating Challenges
Delve into BSX's strategy to overcome tariff impacts and the TAVR exit, while leveraging its robust R&D capabilities to drive future innovations
Read full SWOT analysis

Boston Scientific Corp Earnings Call Summary for Q2/2026

  • Boston Scientific beat Q2 estimates with $0.86 EPS and $5.44B revenue, but cut 2026 organic growth guidance to 5-6% from 5-7%.
  • Shares fell 6.57% to $43.03 on pressure in WATCHMAN and electrophysiology businesses, offsetting strong interventional cardiology growth.
  • Company announced restructuring targeting $500M in run-rate savings by end of 2029; expects limited EPS growth in 2027.
  • Q3 guidance set at 3-5% organic revenue growth and $0.80-$0.82 EPS; full-year 2026 adjusted EPS expected at $3.28-$3.32.
  • Management cited competitive pressures in electrophysiology and slower WATCHMAN demand, with recovery not expected until 2028.
Last Updated: 29/07/2026, 11:12 pm
Read Full Transcript

Earnings

Latest Release
29/07/2026
EPS / Forecast
0.86 / 0.83
Revenue / Forecast
5.44B / 5.37B
EPS Revisions
Last 90 days

BSX Income Statement

Compare BSX to Peers and Sector

Metrics to compare
BSX
Peers
Sector
Relationship
P/E Ratio
19.6x41.5x−0.4x
PEG Ratio
0.40−0.700.00
Price/Book
2.8x3.6x2.6x
Price / LTM Sales
3.4x3.2x3.0x
Upside (Analyst Target)
28.4%25.0%56.0%
Fair Value Upside
Unlock12.5%9.1%Unlock

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
684.98M46.08%32.01B
Other Institutional Investors
691.51M46.52%32.31B
Public Companies & Retail Investors
109.87M7.39%5.13B
Total
1.49B100.00%69.46B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.8.87%131,822,0376,160,044
Vanguard Capital Management, LLC6.49%96,411,5684,505,313

People Also Watch

404.26
HCA
+0.41%
127.14
DG
+0.07%
6.97
BHC
+1.16%
106.57
FUTU
+1.38%

FAQ

What Is the Boston Scientific (BSX) Stock Price Today?

The Boston Scientific stock price today is 48.18 USD.

What Stock Exchange Does Boston Scientific Trade On?

Boston Scientific is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Boston Scientific?

The stock symbol for Boston Scientific is "BSX."

What Is the Boston Scientific Market Cap?

As of today, Boston Scientific market cap is 71.61B USD.

What Is Boston Scientific's Earnings Per Share (TTM)?

The Boston Scientific EPS (TTM) is 2.47.

When Is the Next Boston Scientific Earnings Date?

Boston Scientific will release its next earnings report on 28/10/2026.

From a Technical Analysis Perspective, Is BSX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Boston Scientific Stock Split?

Boston Scientific has split 2 times.

How Many Employees Does Boston Scientific Have?

Boston Scientific has 59000 employees.

What is the current trading status of Boston Scientific (BSX)?

As of 03/08/2026, Boston Scientific (BSX) is trading at a price of 48.18 USD, with a previous close of 46.73 USD. The stock has fluctuated within a day range of 47.50 USD to 48.92 USD, while its 52-week range spans from 42.20 USD to 109.50 USD.

What Is Boston Scientific (BSX) Price Target According to Analysts?

The average 12-month price target for Boston Scientific is 62.69 USD, with a high estimate of 94 USD and a low estimate of 44 USD. 26 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +30.12% Upside potential.

What Is the BSX Premarket Price?

BSX's last pre-market stock price is 47.60 USD. The pre-market share volume is 79,670.00, and the stock has decreased by 0.87, or 1.86%.

What Is the BSX After Hours Price?

BSX's last after hours stock price is 46.78 USD, the stock has decreased by 0.05, or 0.11%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.